It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neovascularization of the erectile tissue emerges as a beneficial curative approach to treat erectile dysfunction (ED). Here we for the first time report the unexpected role of vasohibin-1 (VASH1), mainly known as an anti-angiogenic factor, in restoring erectile function in diabetic mice. A diabetic patient has lower cavernous VASH1 expression than in the potent man. VASH1 was mainly expressed in endothelial cells. There were significant decreases in cavernous endothelial cell and pericyte contents in VASH1 knockout mice compared with those in wild-type mice, which resulted in impairments in erectile function. Intracavernous injection of VASH1 protein successfully restored erectile function in the diabetic mice (~ 90% of control values). VASH1 protein reinstated endothelial cells, pericytes, and endothelial cell–cell junction proteins and induced phosphorylation of eNOS (Ser1177) in the diabetic mice. The induction of angiogenic factors, such as angiopoietin-1 and vascular endothelial growth factor, is responsible for cavernous angiogenesis and the restoration of erectile function mediated by VASH1. Altogether, these findings suggest that VASH1 is proangiogenic in diabetic penis and is a new potential target for diabetic ED.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Inha University School of Medicine, National Research Center for Sexual Medicine and Department of Urology, Incheon, Republic of Korea (GRID:grid.202119.9) (ISNI:0000 0001 2364 8385)
2 Inha University School of Medicine, National Research Center for Sexual Medicine and Department of Urology, Incheon, Republic of Korea (GRID:grid.202119.9) (ISNI:0000 0001 2364 8385); Kosin University College of Medicine, Department of Anatomy, Busan, Republic of Korea (GRID:grid.411144.5) (ISNI:0000 0004 0532 9454)
3 Tohoku University, Department of Vascular Biology, Institute of Development, Aging and Cancer, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
4 Inha University School of Medicine, Department of Drug Development, Incheon, Republic of Korea (GRID:grid.202119.9) (ISNI:0000 0001 2364 8385)